GLP-1 Market
LLY $1427.28 ▼ -0.7% NVO $40.65 ▼ -1.1% PFE $28.83 ▼ -2.1% VKTX $27.58 ▼ -3.0% KLRA $13.21 ▼ -8.1% GPCR $19.84 ▼ -5.3% RHHBY $60.57 • 0.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Nogapendekin Alfa

Company
National Cancer Institute (NCI)
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
6 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

6 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 13, 2026

Find a Clinical Trial Near Me

See recruiting studies for Nogapendekin Alfa and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05618925

    Study for Subjects With Relapsed/Refractory Non- Hodgkin Lymphoma

    Not yet reported ImmunityBio, Inc. 20 participants Est. completion 2027-03-15 2 sites Stand-alone
    Other conditions: Non Hodgkin's Lymphoma Refractory/Relapsed
    View official trial listing →
  • Recruiting NCT NCT06239220

    PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC

    Not yet reported Dana-Farber Cancer Institute 25 participants Est. completion 2027-03-31 2 sites
    Other conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07108036

    A Study to Assess Anktiva in Patients With Long Covid-19.

    Not yet reported ImmunityBio, Inc. 20 participants Est. completion 2026-10 1 site
    Other conditions: Long COVID
    View official trial listing →
  • Recruiting NCT NCT07123727

    A Study to Examine Anktiva for the Treatment of COVID-19.

    Not yet reported ImmunityBio, Inc. 40 participants Est. completion 2027-03 1 site Stand-alone
    Other conditions: Long COVID, Long COVID Syndrome, Long Covid 19
    View official trial listing →
  • Recruiting NCT NCT07261657

    N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive Cellular Therapy

    Not yet reported Seth Pollack 8 participants Est. completion 2032-09-02 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Synovial Sarcoma
    View official trial listing →
  • Recruiting NCT NCT07355205

    First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported Washington University School of Medicine 26 participants Est. completion 2032-07-31 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent
    View official trial listing →
  • Completed NCT NCT03493945

    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

    Not yet reported, Not yet reported National Cancer Institute (NCI) 59 participants Est. completion 2024-10-08 1 site Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Prostate Neoplasm, Advanced Solid Tumor, Solid Tumor, Non-metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT03520686

    Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

    Not yet reported ImmunityBio, Inc. 102 participants Est. completion 2025-10-13 31 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT04247282

    Anti-PD-L1/TGF-beta Trap (M7824) Alone and in Combination With TriAd Vaccine and N-803 for Resectable Head and Neck Squamous Cell Carcinoma Not Associated With Human Papillomavirus Infection

    Not yet reported, Not yet reported National Cancer Institute (NCI) 21 participants Est. completion 2023-06-12 1 site
    Other conditions: Head and Neck Cancer, Head and Neck Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT05096663

    Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

    Not yet reported, Not yet reported SWOG Cancer Research Network 82 participants Est. completion 2027-12-01 350 sites Stand-alone
    Other conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
    View official trial listing →
  • Active, not recruiting NCT NCT05419011

    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome

    Not yet reported National Cancer Institute (NCI) 186 participants Est. completion 2028-01-01 14 sites Stand-alone
    Other conditions: Colorectal Carcinoma, Colorectal Neoplasm, Lynch Syndrome
    View official trial listing →
  • Active, not recruiting NCT NCT06061809

    N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

    Not yet reported ImmunityBio, Inc. 34 participants Est. completion 2030-12-31 4 sites
    Other conditions: Glioblastoma
    View official trial listing →
  • Available NCT NCT06956547

    Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

    ImmunityBio, Inc. 1 site
    Other conditions: Lymphopenia
    View official trial listing →
  • Enrolling by invitation NCT NCT07145164

    Interleukin-15 to Promote Post-ART Control of HIV

    Not yet reported Michael Peluso, MD 20 participants Est. completion 2028-12 1 site
    Other conditions: HIV
    View official trial listing →
  • Not yet recruiting NCT NCT07217496

    N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

    Not yet reported ImmunityBio, Inc. 18 participants Est. completion 2032-01 1 site Stand-alone
    Other conditions: Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer, Bladder Cancer
    View official trial listing →
  • Withdrawn NCT NCT07488884

    Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer

    Not yet reported ImmunityBio, Inc. Est. completion 2029-06-01 Stand-alone
    Other conditions: Pancreatic Cancer Resectable, Pancreatic Cancer
    View official trial listing →
  • Withdrawn NCT NCT07492875

    Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia

    Not yet reported ImmunityBio, Inc. Est. completion 2029-12-31 Stand-alone
    Other conditions: Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS), Sepsis, Lymphopenia, Immunoparalysis
    View official trial listing →
  • Withdrawn NCT NCT07492888

    Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS)

    Not yet reported ImmunityBio, Inc. Est. completion 2027-01-15 Stand-alone
    Other conditions: Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum, Sepsis, Lymphopenia / Immunoparalysis in Critically Ill Adults
    View official trial listing →
  • Withdrawn NCT NCT07524257

    Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC

    Not yet reported ImmunityBio, Inc. Est. completion 2029-12-30 Stand-alone
    Other conditions: NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC
    View official trial listing →
  • Withdrawn NCT NCT07551544

    ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer

    Not yet reported ImmunityBio, Inc. Est. completion 2032-05 Stand-alone
    Other conditions: NMIBC
    View official trial listing →
  • Not yet recruiting NCT NCT07578558

    NAI for Sepsis With Persistent Lymphopenia

    Not yet reported ImmunityBio, Inc. 50 participants Est. completion 2027-10-04 Stand-alone
    Other conditions: Sepsis, Septic Shock, Lymphopenia, Immunosuppression, Critical Illness
    View official trial listing →
  • Not yet recruiting NCT NCT07628062

    Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation

    Not yet reported ImmunityBio, Inc. 70 participants Est. completion 2031-06-27 Stand-alone
    Other conditions: HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07783789

    NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis

    Not yet reported ImmunityBio, Inc. 50 participants Est. completion 2028-08-13 Stand-alone
    Other conditions: Sepsis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Nogapendekin Alfa, ANKTIVA

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.